Galmed Pharmaceuticals (NASDAQ: GLMD)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.320 | -0.240 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Galmed Pharmaceuticals (NASDAQ: GLMD) through any online brokerage.
There are no as such competitors for Galmed Pharmaceuticals.
The latest price target for Galmed Pharmaceuticals (NASDAQ: GLMD) was reported by Raymond James on Wednesday, May 18, 2022. The analyst firm set a price target for 0.00 expecting GLMD to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
The stock price for Galmed Pharmaceuticals (NASDAQ: GLMD) is $0.6 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Galmed Pharmaceuticals.
Galmed Pharmaceuticals’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Galmed Pharmaceuticals.
Galmed Pharmaceuticals is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.